Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections
The association between viral load and cardiovascular disease risk has been under-investigated among young people with HIV.
Researchers studied surveys on self-rated internalized HIV stigma and compared those findings with the rate of retention in medical care.
Buprenorphine is a treatment for people with opioid use disorder.
Research indicates that there are numerous differences in how HIV behaves in women versus men.
Studies have found that weight gain is common after people with HIV begin an antiretroviral in this class.
A session at CROI 2020 focused on HIV prevalence and outcomes in these understudied populations.
A recent Japanese study found that this risk reduction was greater than that associated with the hep B vaccine.
Researchers found that among those older than 50, lung function declined at a comparable rate regardless of HIV status.
That said, researchers identified risk factors that could be modified to eliminate the racial disparity.
Researchers are looking for ways to reduce the doses needed for on-demand PrEP and the 30-day duration recommended for PEP.
This may not lower PrEP’s efficacy, but very strict adherence to the daily Truvada regimen is key for pregnant women.
Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.
Pomalyst led to resolution of anal precancer in men with or without HIV.
Researchers compared the rate of first-time blood donors who tested positive for HIV before and after the new deferral policy.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.